INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 178 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $327,100 | -80.6% | 26,443 | +160.5% | 0.57% | -27.5% |
Q3 2015 | $1,682,000 | -71.9% | 10,150 | -59.0% | 0.79% | -59.2% |
Q2 2015 | $5,978,000 | -56.9% | 24,743 | -49.6% | 1.93% | -42.1% |
Q1 2015 | $13,854,000 | +129.3% | 49,137 | +26.9% | 3.34% | +110.2% |
Q4 2014 | $6,042,000 | +158.5% | 38,732 | +292.2% | 1.59% | +90.8% |
Q3 2014 | $2,337,000 | – | 9,876 | – | 0.83% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |